Chronic Daily Headache
High-dose Botox shows promise as prophylactic treatment
Published in Clinical Trials Week, November 14th, 2005
Scientists in the United States conducted a clinical trial to "identify a treatment-responsive population for botulinum toxin type A (BoNTA) and to evaluate the safety and efficacy of three different doses of BoNTA as prophylactic treatment" of CDH.
"A randomized, double-blind, placebo-controlled study of BoNTA in patients with CDH was conducted from July 6, 2001, through November 7, 2003, at 28 North American study centers," explained S.D. Silberstein and coauthors working at Thomas Jefferson University Hospital. "Eligible patients were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2005-11-14)
More Articles from Clinical Trials Week
- Clinical Trials
Study shows interferon treatment delays MS onset in patients showing clinical signs - Crohn Disease
Phase II Trial results for treatment of Crohn Disease with Cimzia are positive - Drug Development
Data being analyzed in phase II CoFactor trial in patients with metastatic colorectal cancer - Erectile Dysfunction
Tadalafil effective during thiazide diuretic hypertension therapy - Adverse Drug Reaction
Tysabri safety evaluation complete; no new confirmed cases of PML - Alcoholism Therapy
Increasing leptin levels precede relapse in detoxified alcoholics - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
